Acute and continuation pharmacological treatment of children and adolescents with bipolar disorders; a summary of two previous studies

R. A. Kowatch, Th J. Carmody, T. Suppes, J. H. Hume, M. Kromelis, G. J. Emslie, W. A. Weinberg

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We report the results of an acute-phase and continuation-phase study of the pharmacological treatment of children and adolescents with bipolar disorders. The acute phase study, with a duration of 6-8 weeks, aimed at developing effect sizes (ES) for lithium, divalproex sodium, and carbamazepine, in the acute phase treatment of Bipolar I or II children and adolescents during a mixed or manic episode. During the acute-phase of treatment, 42 outpatients with a mean age of 11.4 yr. (20 with Bipolar I Disorder and 22 with Bipolar II Disorder) were randomly assigned to 6-8 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly CGI Improvement scores and the Young Mania Rating Scale. Using a ≥ 50% change from baseline to exit in the Y-MRS scores to define response, the effect size for divalproex sodium was 1.63, 1.06 for lithium, and 1.00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were: sodium divalproex 53%; lithium 38%; and carbamazepine 38% (χ2=0.85, 2 d.f., p=0.60). Thirty-five subjects continued in open, treatment for another 16-18 weeks, for a total of 24 weeks of prospective treatment. Overall, of the thirty-five continuation phase subjects, thirty (85%) were categorized as responders at the end of the continuation phase of treatment. Of these thirty-five subjects, 13 (37%) were only on a single mood stabilizer and no other psychotropic agents at the end of the continuation phase. Thirty-one percent of subjects in continuation were also treated with astimulant medication in addition to mood stabilizers.

Original languageEnglish (US)
Pages (from-to)145-149
Number of pages5
JournalActa Neuropsychiatrica
Volume12
Issue number3
StatePublished - 2000

Fingerprint

Bipolar Disorder
Pharmacology
Carbamazepine
Valproic Acid
Lithium
Therapeutics
Outpatients

Keywords

  • Adolescents
  • Bipolar disorder
  • Carbamazepine
  • Children
  • Divalproex sodium
  • Lithium

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Acute and continuation pharmacological treatment of children and adolescents with bipolar disorders; a summary of two previous studies. / Kowatch, R. A.; Carmody, Th J.; Suppes, T.; Hume, J. H.; Kromelis, M.; Emslie, G. J.; Weinberg, W. A.

In: Acta Neuropsychiatrica, Vol. 12, No. 3, 2000, p. 145-149.

Research output: Contribution to journalArticle

@article{5f5fddd074814e5c9dc72511c884d8e0,
title = "Acute and continuation pharmacological treatment of children and adolescents with bipolar disorders; a summary of two previous studies",
abstract = "We report the results of an acute-phase and continuation-phase study of the pharmacological treatment of children and adolescents with bipolar disorders. The acute phase study, with a duration of 6-8 weeks, aimed at developing effect sizes (ES) for lithium, divalproex sodium, and carbamazepine, in the acute phase treatment of Bipolar I or II children and adolescents during a mixed or manic episode. During the acute-phase of treatment, 42 outpatients with a mean age of 11.4 yr. (20 with Bipolar I Disorder and 22 with Bipolar II Disorder) were randomly assigned to 6-8 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly CGI Improvement scores and the Young Mania Rating Scale. Using a ≥ 50{\%} change from baseline to exit in the Y-MRS scores to define response, the effect size for divalproex sodium was 1.63, 1.06 for lithium, and 1.00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were: sodium divalproex 53{\%}; lithium 38{\%}; and carbamazepine 38{\%} (χ2=0.85, 2 d.f., p=0.60). Thirty-five subjects continued in open, treatment for another 16-18 weeks, for a total of 24 weeks of prospective treatment. Overall, of the thirty-five continuation phase subjects, thirty (85{\%}) were categorized as responders at the end of the continuation phase of treatment. Of these thirty-five subjects, 13 (37{\%}) were only on a single mood stabilizer and no other psychotropic agents at the end of the continuation phase. Thirty-one percent of subjects in continuation were also treated with astimulant medication in addition to mood stabilizers.",
keywords = "Adolescents, Bipolar disorder, Carbamazepine, Children, Divalproex sodium, Lithium",
author = "Kowatch, {R. A.} and Carmody, {Th J.} and T. Suppes and Hume, {J. H.} and M. Kromelis and Emslie, {G. J.} and Weinberg, {W. A.}",
year = "2000",
language = "English (US)",
volume = "12",
pages = "145--149",
journal = "Acta Neuropsychiatrica",
issn = "0924-2708",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Acute and continuation pharmacological treatment of children and adolescents with bipolar disorders; a summary of two previous studies

AU - Kowatch, R. A.

AU - Carmody, Th J.

AU - Suppes, T.

AU - Hume, J. H.

AU - Kromelis, M.

AU - Emslie, G. J.

AU - Weinberg, W. A.

PY - 2000

Y1 - 2000

N2 - We report the results of an acute-phase and continuation-phase study of the pharmacological treatment of children and adolescents with bipolar disorders. The acute phase study, with a duration of 6-8 weeks, aimed at developing effect sizes (ES) for lithium, divalproex sodium, and carbamazepine, in the acute phase treatment of Bipolar I or II children and adolescents during a mixed or manic episode. During the acute-phase of treatment, 42 outpatients with a mean age of 11.4 yr. (20 with Bipolar I Disorder and 22 with Bipolar II Disorder) were randomly assigned to 6-8 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly CGI Improvement scores and the Young Mania Rating Scale. Using a ≥ 50% change from baseline to exit in the Y-MRS scores to define response, the effect size for divalproex sodium was 1.63, 1.06 for lithium, and 1.00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were: sodium divalproex 53%; lithium 38%; and carbamazepine 38% (χ2=0.85, 2 d.f., p=0.60). Thirty-five subjects continued in open, treatment for another 16-18 weeks, for a total of 24 weeks of prospective treatment. Overall, of the thirty-five continuation phase subjects, thirty (85%) were categorized as responders at the end of the continuation phase of treatment. Of these thirty-five subjects, 13 (37%) were only on a single mood stabilizer and no other psychotropic agents at the end of the continuation phase. Thirty-one percent of subjects in continuation were also treated with astimulant medication in addition to mood stabilizers.

AB - We report the results of an acute-phase and continuation-phase study of the pharmacological treatment of children and adolescents with bipolar disorders. The acute phase study, with a duration of 6-8 weeks, aimed at developing effect sizes (ES) for lithium, divalproex sodium, and carbamazepine, in the acute phase treatment of Bipolar I or II children and adolescents during a mixed or manic episode. During the acute-phase of treatment, 42 outpatients with a mean age of 11.4 yr. (20 with Bipolar I Disorder and 22 with Bipolar II Disorder) were randomly assigned to 6-8 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly CGI Improvement scores and the Young Mania Rating Scale. Using a ≥ 50% change from baseline to exit in the Y-MRS scores to define response, the effect size for divalproex sodium was 1.63, 1.06 for lithium, and 1.00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were: sodium divalproex 53%; lithium 38%; and carbamazepine 38% (χ2=0.85, 2 d.f., p=0.60). Thirty-five subjects continued in open, treatment for another 16-18 weeks, for a total of 24 weeks of prospective treatment. Overall, of the thirty-five continuation phase subjects, thirty (85%) were categorized as responders at the end of the continuation phase of treatment. Of these thirty-five subjects, 13 (37%) were only on a single mood stabilizer and no other psychotropic agents at the end of the continuation phase. Thirty-one percent of subjects in continuation were also treated with astimulant medication in addition to mood stabilizers.

KW - Adolescents

KW - Bipolar disorder

KW - Carbamazepine

KW - Children

KW - Divalproex sodium

KW - Lithium

UR - http://www.scopus.com/inward/record.url?scp=0033832623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033832623&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033832623

VL - 12

SP - 145

EP - 149

JO - Acta Neuropsychiatrica

JF - Acta Neuropsychiatrica

SN - 0924-2708

IS - 3

ER -